CompanyGraph
Tianjin Chase Sun Pharmaceutical Co., Ltd.
300026 · SZSE · China
chasesun.cnFinancials as of FY2024–FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.52B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.23: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.29%Below 5Y avg (0.74%)
Annual Rate
CNY 0.01Paid annual
Payout Ratio
300.0%High
Last Ex-Dividend
Jul 15, 2026
The reported statements, read against the company's own industry.
The statements on file don't all cover the same year: income statement FY2025, balance sheet FY2024, cash-flow statement FY2024. Each figure below is labelled with the year it comes from.
Financials view
Market Capitalization
10.24BCNY1.52B · vs all stocks (USD)
Trailing P/E
364.00xRevenue (TTM)
4.68BCNY694.86M · vs all stocks (USD)
Profit Margin
0.51%Beta
0.0280xvs all stocks
52-Week Change
-20.14%vs all stocks
Market Capitalization
10.24BCNY1.52B · vs all stocks (USD)
Enterprise Value
10.03BCNY1.49B · vs all stocks (USD)
Trailing P/E
364.00xForward P/E
8.88xPrice to Sales (TTM)
2.34xPrice to Book (MRQ)
1.27xEnterprise to Revenue
2.15xEnterprise to EBITDA
22.27xGross Margin
57.43%Profit Margin
0.51%Operating Margin
8.11%Return on Assets (TTM)
1.07%Return on Equity (TTM)
0.33%Revenue (TTM)
4.68BCNY694.86M · vs all stocks (USD)
Revenue per Share (TTM)
2.44CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-18.90%Gross Profit (TTM)
2.67BCNY397.04M · vs all stocks (USD)
EBITDA (TTM)
450.66MCNY66.93M · vs all stocks (USD)
Net Income (TTM)
23.88MCNY3.55M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
8.90%Operating Cash Flow (TTM)
798.77MCNY118.63M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
731.10MCNY108.58M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0100CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.29%vs all stocks
5-Year Average Dividend Yield
0.74%vs all stocks
Payout Ratio
300.00%Minority Interest (Equity)
154.66MCNYFY2024 · Dec 31, 2024EPS (Basic)
0.0100CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.85BSharesFY2025 · Dec 31, 2025Operating Cash Flow
161.73MCNYFY2024 · Dec 31, 2024Free Cash Flow
-31.00MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
1.27BCNYFY2024 · Dec 31, 2024Starting Profit (CF Statement)
22.95MCNYFY2024 · Dec 31, 2024Other Non-cash Items
68.15MCNYFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
-10.92MCNYFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
81.56MCNYFY2024 · Dec 31, 2024Capital Expenditures
-192.73MCNYFY2024 · Dec 31, 2024Sale of Investments
6.79MCNYFY2024 · Dec 31, 2024Other Investing Activity
15.67MCNYFY2024 · Dec 31, 2024Net Investing Cash Flow
-170.26MCNYFY2024 · Dec 31, 2024Long-term Debt Issuance
56.51MCNYFY2024 · Dec 31, 2024Long-term Debt Payments
-814.67MCNYFY2024 · Dec 31, 2024Common Dividends Paid
-137.11MCNYFY2024 · Dec 31, 2024Other Financing Charges
-57.37MCNYFY2024 · Dec 31, 2024Net Financing Cash Flow
-952.64MCNYFY2024 · Dec 31, 2024Shares Outstanding
3.00BSharesUpdated Aug 19, 2026Float Shares
1.90BSharesUpdated Aug 19, 2026% Held by Insiders
42.97%vs all stocks
% Held by Institutions
1.75%vs all stocks
Total Cash (MRQ)
1.56BCNY231.35M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5190CNYUpdated Aug 19, 2026Total Debt (MRQ)
516.04MCNY76.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0592xCurrent Ratio (MRQ)
4.70xBook Value per Share (MRQ)
2.86CNYUpdated Aug 19, 2026Total Assets
11.17BCNY1.66B · vs all stocks (USD)
Total Current Assets
6.15BCNYFY2024 · Dec 31, 2024Total Liabilities
2.37BCNYFY2024 · Dec 31, 2024Total Non-current Assets
5.02BCNYFY2024 · Dec 31, 2024Total Non-current Liabilities
745.41MCNYFY2024 · Dec 31, 2024Total Current Liabilities
1.62BCNYFY2024 · Dec 31, 2024Cash
1.26BCNYFY2024 · Dec 31, 2024Cash Equivalents
50.51MCNYFY2024 · Dec 31, 2024Cash & Cash Equivalents
1.31BCNYFY2024 · Dec 31, 2024Accounts Receivable
2.66BCNYFY2024 · Dec 31, 2024Inventory
1.75BCNYFY2024 · Dec 31, 2024Accounts Payable
678.15MCNYFY2024 · Dec 31, 2024Short-term Debt
211.74MCNYFY2024 · Dec 31, 2024Other Current Liabilities
7.08MCNYFY2024 · Dec 31, 2024Long-term Debt
640.33MCNYFY2024 · Dec 31, 2024Common Stock (Book)
3.00BCNYFY2024 · Dec 31, 2024Retained Earnings
4.74BCNYFY2024 · Dec 31, 2024Total Shareholders' Equity
8.80BCNY1.31B · vs all stocks (USD)
52-Week Low
2.82CNYUpdated Aug 19, 202652-Week High
4.36CNYUpdated Aug 19, 202652-Week Change
-20.14%vs all stocks
Beta
0.0280xvs all stocks
50-Day MA
3.24CNYUpdated Aug 19, 2026200-Day MA
3.49CNYUpdated Aug 19, 2026Avg 10-Day Volume
102.49MSharesUpdated Aug 19, 2026Avg 30-Day Volume
82.93MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.0100CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.57Profit Margin: 0.01
Financial Health
Altman Z-Score 4.23: safe zoneNotable
Altman Z-Score: 4.23
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.52B, above the global median of $1.15BNotable
Market cap (USD): 1,521,463,830.469Global Median: 1,146,734,693.424
Revenue is $694.86M, above the global median of $520.53MNotable
Revenue (USD): 694,863,191.122Global Median: 520,528,949.311
Levered free cash flow is $108.58M, above the global median of $16.24MNotable
Levered free cash flow (USD): 108,582,235.341Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mayinglong Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Pacific Shuanglin Bio-Pharmacy Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Zhejiang Jolly Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Integra LifeSciences Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Arrivent Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk